Xiaobin Li

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma

Jin Y. Jin, L. Gibiansky, S. Girish, 2019, CPT: pharmacometrics & systems pharmacology.

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma

Jin Y. Jin, S. Girish, D. Lu, 2020, Cancer Chemotherapy and Pharmacology.

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

L. Gibiansky, S. Girish, Rong Shi, 2020, Cancer Chemotherapy and Pharmacology.

Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma

Xiaobing Duan, Xian-Yang Li, Meixiao Zhan, 2023, Frontiers in Immunology.

Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study

L. Gibiansky, A. Kater, S. Girish, 2020, Leukemia & lymphoma.

Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study

L. Gibiansky, A. Kater, S. Girish, 2019, Clinical Pharmacokinetics.

Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma

L. Gibiansky, S. Girish, Rong Shi, 2020, Leukemia & lymphoma.